Clinical Trial Update: EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 study comparing EP-100 in combination with paclitaxel versus paclitaxel alone in patients with recurrent ovarian cancer; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• EP-100
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Esperance Pharmaceuticals Inc | Conditions: Ovarian Cancer Recurrent | Phase 2 | Status: COMPLETED